Researchers have published several recent studies on advances in DM research.
Ionis Pharmaceuticals (formerly Isis Pharmaceuticals, Inc.) announced the identification of a drug development candidate, IONIS-DMPKRx, designed to treat Myotonic Dystrophy Type 1 (DM1), which they plan to advance into human clinical trials next year.
Researchers from the University of Rochester recently summarized the “diagnostic odyssey” experienced by a group of 814 individuals with myotonic dystrophy.
Nicholas Johnson, MD, and researchers at the University of Rochester recently published an article in The Journal of Child Neurology that describes the impact of childhood and congenital myotonic dystrophy on quality of life.
Maurice Swanson, Ph.D., Professor of Molecular Genetics and Microbiology at University of Florida, Gainesville, and a team of researchers have found that the muscleblind-like 2 (MBNL2) protein in the central nervous system (CNS) may be responsible for the neurological impacts of myotonic dystrophy